Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Page 1
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.
Novak G, Streffer JR, Timmers M, Henley D, Brashear HR, Bogert J, Russu A, Janssens L, Tesseur I, Tritsmans L, Van Nueten L, Engelborghs S. Novak G, et al. Among authors: brashear hr. Alzheimers Res Ther. 2020 May 14;12(1):58. doi: 10.1186/s13195-020-00614-5. Alzheimers Res Ther. 2020. PMID: 32410694 Free PMC article. Clinical Trial.
BACKGROUND: Atabecestat, a potent brain-penetrable inhibitor of BACE1 activity that reduces CSF amyloid beta (Abeta), was developed for oral treatment for Alzheimer's disease (AD). The long-term safety and effect of atabecestat on cognitive performance in participants with …
BACKGROUND: Atabecestat, a potent brain-penetrable inhibitor of BACE1 activity that reduces CSF amyloid beta (Abeta), was developed for oral …
Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study.
Salloway S, Marshall GA, Lu M, Brashear HR. Salloway S, et al. Among authors: brashear hr. Curr Alzheimer Res. 2018;15(13):1231-1243. doi: 10.2174/1567205015666180821114813. Curr Alzheimer Res. 2018. PMID: 30129411 Clinical Trial.
OBJECTIVE: This phase 2, open-label extension (OLE) study evaluated long-term safety and efficacy of bapineuzumab in patients with the mild-to-moderate AD. ...
OBJECTIVE: This phase 2, open-label extension (OLE) study evaluated long-term safety and efficacy of bapineuzumab in patients with th …
Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study.
Salloway SP, Sperling R, Fox NC, Sabbagh MN, Honig LS, Porsteinsson AP, Rofael H, Ketter N, Wang D, Liu E, Carr S, Black RS, Brashear HR. Salloway SP, et al. Among authors: brashear hr. J Alzheimers Dis. 2018;64(3):689-707. doi: 10.3233/JAD-171157. J Alzheimers Dis. 2018. PMID: 29914022 Clinical Trial.
OBJECTIVES: The primary and secondary objectives were to evaluate the long-term safety, tolerability, and maintenance of efficacy of bapineuzumab. ...
OBJECTIVES: The primary and secondary objectives were to evaluate the long-term safety, tolerability, and maintenance of efficacy of …
Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies.
Ivanoiu A, Pariente J, Booth K, Lobello K, Luscan G, Hua L, Lucas P, Styren S, Yang L, Li D, Black RS, Brashear HR, McRae T. Ivanoiu A, et al. Among authors: brashear hr. Alzheimers Res Ther. 2016 Jun 23;8(1):24. doi: 10.1186/s13195-016-0193-y. Alzheimers Res Ther. 2016. PMID: 27334799 Free PMC article. Clinical Trial.
The 3000 and 3001 phase 3 clinical studies of intravenous bapineuzumab assessed safety and efficacy in patients with mild to moderate AD recruited in over 26 countries. This article describes the long-term safety and tolerability of bapineuzumab in the extension studies fo …
The 3000 and 3001 phase 3 clinical studies of intravenous bapineuzumab assessed safety and efficacy in patients with mild to moderate AD rec …
First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.
Delnomdedieu M, Duvvuri S, Li DJ, Atassi N, Lu M, Brashear HR, Liu E, Ness S, Kupiec JW. Delnomdedieu M, et al. Among authors: brashear hr. Alzheimers Res Ther. 2016 Mar 1;8(1):12. doi: 10.1186/s13195-016-0177-y. Alzheimers Res Ther. 2016. PMID: 26925577 Free PMC article. Clinical Trial.
Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease.
Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, Davis B, Richards HM. Hager K, et al. Among authors: brashear hr. Neuropsychiatr Dis Treat. 2014 Feb 21;10:391-401. doi: 10.2147/NDT.S57909. eCollection 2014. Neuropsychiatr Dis Treat. 2014. PMID: 24591834 Free PMC article.
BACKGROUND: Currently available treatments for Alzheimer's disease (AD) can produce mild improvements in cognitive function, behavior, and activities of daily living in patients, but their influence on long-term survival is not well established. This study was designed to …
BACKGROUND: Currently available treatments for Alzheimer's disease (AD) can produce mild improvements in cognitive function, behavior, and a …
Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease.
Kavanagh S, Howe I, Brashear HR, Wang D, van Baelen B, Todd M, Schwalen S. Kavanagh S, et al. Among authors: brashear hr. Curr Alzheimer Res. 2011 Mar;8(2):175-86. doi: 10.2174/156720511795256044. Curr Alzheimer Res. 2011. PMID: 21222607 Free PMC article.
BACKGROUND: This analysis aimed to identify an operational, clinically relevant definition of response achieved in short-term clinical trials to support the identification of patients with Alzheimer's disease (AD) who would benefit most from long-term galantamine th …
BACKGROUND: This analysis aimed to identify an operational, clinically relevant definition of response achieved in short-term clinica …
Analyses of mortality risk in patients with dementia treated with galantamine.
Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Brashear HR, Berlin JA, Battisti WP, Kavanagh S. Feldman HH, et al. Among authors: brashear hr. Acta Neurol Scand. 2009 Jan;119(1):22-31. doi: 10.1111/j.1600-0404.2008.01047.x. Epub 2008 Jun 1. Acta Neurol Scand. 2009. PMID: 18518863
METHODS: (1) Meta-analysis of mortality data from double-blind, placebo-controlled, randomized trials; and (2) recontact study to collect additional longer term mortality data from previous galantamine trial participants. ...Cox regression analyses were consistent with the …
METHODS: (1) Meta-analysis of mortality data from double-blind, placebo-controlled, randomized trials; and (2) recontact study to collect ad …